Arogga LogoArogga Home
Ogivri 440 - Image 1
Out Of Stock

ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন

Register
2595 people viewed this
info-icon
info-icon
info-icon

Ogivri 440

Injection-(440mg/20ml)
brand logo
Beximco Pharmaceuticals Ltd.

Generic: Trastuzumab

1 Injection
৳ 60190
৳ 60190
Alternative Brands For Ogivri 440

Medicine Overview of Ogivri 440mg/20ml Injection

Switch language Iconবাংলা

Introduction

Ogivri 440 is used in the treatment of breast and stomach cancer. It works by killing the cancer cells by inhibiting HER2 (human epidermal growth factor receptor protein). Ogivri 440 is given as an injection by a qualified medical professional. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to. The most common side effects of this medicine include nausea, headache, rash, insomnia, and infection. This medicine may reduce the number of blood cells (decrease red blood and white blood cells) in your blood, thereby, increasing the susceptibility to infections. Regular blood tests are required to check your blood cells along with heart, liver, and blood uric acid levels. You must have to inform your doctor if you experience breathlessness, cough, shivering, swelling of legs and arm. Many other medicines can affect, or be affected by, this medicine so let your healthcare team know all medications you are using. This medicine is not recommended during pregnancy or while breastfeeding. The use of effective contraception by both males and females during treatment is important to avoid pregnancy.

Uses of Ogivri 440

  • Breast cancer
  • Stomach cancer

Side effects of Ogivri 440

Common
  • Anemia (low number of red blood cells)
  • Chills
  • Common cold
  • Cough
  • Decreased blood cells (red cells, white cells, and platelets)
  • Diarrhea
  • Fatigue
  • Fever
  • Headache
  • Heart failure
  • Infection
  • Insomnia (difficulty in sleeping)
  • Mucosal inflammation
  • Nausea
  • Rash
  • Stomatitis (Inflammation of the mouth)
  • Taste change
  • Upper respiratory tract infection
  • Weight loss

How to use Ogivri 440

Your doctor or nurse will give you this medicine. Kindly do not self administer.

How Ogivri 440 works

Ogivri 440 is a recombinant IgG1 monoclonal antibody. It works against the HER2 (human epidermal growth factor receptor protein) receptors which are responsible for the over-proliferation of cancer cells in breast cancer and stomach cancer cells. It destroys the cancer cells by inhibiting HER2. It also inhibits various cancer-causing downstream signaling pathways.

What if you forget to take Ogivri 440?

If you miss a dose of Ogivri 440, please consult your doctor.

Quick Tips

  • It is given as an injection into your vein or under the skin, usually over 1 hour.
  • Use effective contraception method to prevent pregnancy while taking this medicine and for 7 months after you stop the treatment.
  • Your doctor will monitor your heart regularly while taking this medicine. Inform your doctor if you notice symptoms such as breathlessness, cough, shivering, swelling of legs and arm.
  • Inform your doctor if you are pregnant, planning pregnancy or breastfeeding.

Brief Description

Indication

Breast cancer, Gastric cancer

Administration

IV Administration Not for IV push or bolus administration Administer initial IV infusion over 90 min Subsequent weekly IV infusions may be administered over 30 min if prior infusions are well tolerated

Adult Dose

Intravenous Breast Cancer Adjuvant treatment Indicated for adjuvant treatment of HER-2 overexpressing breast cancer Administer during and following paclitaxel, docetaxel, or docetaxel/carboplatin 4 mg/kg IV over 90 minutes, THEN 2 mg/kg IV over 30 minutes qWeek during chemotherapy for the first 12 weeks (paclitaxel or docetaxel) or 18 weeks (docetaxel/carboplatin) One week following the last weekly dose administer at 6 mg/kg as an IV infusion over 30?90 min every three weeks As single agent within three wk following completion of multi-modality, anthracycline based chemotherapy regimens: Initial dose at 8 mg/kg as an IV infusion over 90 min; subsequent doses at 6 mg/kg as an IV infusion over 30?90 min every three wks Extending adjuvant treatment beyond one year not recommended Metastatic breast cancer Treat as a single agent or in combination with paclitaxel 4 mg/kg IV over 90 minutes, THEN 2 mg/kg IV over 30 minutes qWeek Gastric Cancer Indicated for treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma Administered in combination with cisplatin and capecitabine or 5-fluorouracil who have not received prior treatment for metastatic disease First cycle: 8 mg/kg IV; infuse IV over 90 min Subsequent cycles: 6 mg/kg IV q3wk; infuse IV over 30-90 min Continue q3week cycles until disease progression

Child Dose

Safety and efficacy not established

Contraindication

Lactation (start only 6 mth after last dose of drug). Do not admin by rapid IV or bolus inj.

Mode of Action

Trastuzumab, a monoclonal antibody, has action directed against a cell surface protein produced by human epidermal growth factor receptor 2 (HER2). It inhibits proliferation of tumour cells that overexpress HER2 e.g. in 1/3 of breast cancer.

Precaution

Patient w/ pre-existing CV and pulmonary disease; extensive pulmonary tumour involvement. Pregnancy and lactation. Monitoring Parameters Monitor cardiac function prior and during treatment. Lactation: not known if excreted in breast milk, discontinue nursing during treatment and for 6 months after last dose

Side Effect

>10% Pain (47%),Asthenia (42%),Fever (36%),Nausea (33%),Chills (32%),Cough (26%),Headache (26%),Diarrhea (25%),Vomiting (23%),Abdominal pain (22%),Back pain (22%),Dyspnea (22%),Infection (20%),Rash (18%),Anorexia (14%),Insomnia (14%),Dizziness (13%) 1-10% Flu-like syndrome (10%),Peripheral edema (10%),CHF (7%),Depression (6%),Tachycardia (5%),UTI (5%),Anemia (4%),Hypersensitivity (3%),Leukopenia (3%) Potentially Fatal: Severe hypersensitivity (anaphylaxis) and infusion reactions; pulmonary events e.g. acute respiratory distress syndrome; cardiotoxicity. Neutropenia (especially when given with chemotherapy).

Interaction

Increased risk of severe cardiotoxicity with anthracyclines. Increased risk of leukopenia and anaemia in combination chemotherapy (e.g. paclitaxel). Paclitaxel may decrease the clearance of trastuzumab. Increased risk of bleeding with warfarin.

Buy Ogivri 440 from Arogga

In Bangladesh, you can get the original Ogivri 440. Select your favorite one from a large collection of medicine products. Order from App to get more offers and better experience.

What is the price of Ogivri 440 in Bangladesh?

The latest price of Ogivri 440 in Bangladesh is 60190৳. You can buy Ogivri 440 at the best price from Arogga. Order online through our website or mobile app and get fast home delivery anywhere in Bangladesh. Cash on Delivery (COD) is available all over Bangladesh.

Frequently Questions & Answers

Is the product authentic?

Yes. Arogga sources all medicines and health products directly from trusted suppliers, distributors, or manufacturers. Every product is verified before delivery.

Does Arogga deliver all over Bangladesh?

Yes, Arogga delivers nationwide. You can order from anywhere in Bangladesh.

Is Cash on Delivery(COD) available?

Yes, Cash on Delivery is available across Bangladesh for most products.

How long does delivery take?

Delivery usually takes 24–48 hours inside Dhaka and 3–5 days outside Dhaka, depending on location and courier load.

Can I return or replace the product?

If the product is damaged, incorrect, or expired, you can request a replacement or refund according to Arogga’s return policy.

Safety Advices

Rocket Icon
UNSAFE
Ogivri 440 may cause excessive drowsiness with alcohol.
Rocket Icon
CONSULT YOUR DOCTOR
Ogivri 440 is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
Rocket Icon
CONSULT YOUR DOCTOR
Ogivri 440 is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Rocket Icon
CONSULT YOUR DOCTOR
It is not known whether Ogivri 440 alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
Rocket Icon
SAFE IF PRESCRIBED
Ogivri 440 is probably safe to use in patients with kidney disease. Limited data available suggests that dose adjustment of Ogivri 440 may not be needed in these patients. Please consult your doctor.
Rocket Icon
CONSULT YOUR DOCTOR
There is limited information available on the use of Ogivri 440 in patients with liver disease. Please consult your doctor.

You May Also Like

see all

More from Beximco Pharmaceuticals Ltd.

see all
Disclaimer

The information provided herein is accurate, updated and complete as per the best practices of the Company. Please note that this information should not be treated as a replacement for physical medical consultation or advice. We do not guarantee the accuracy and the completeness of the information so provided. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company. We do not take any responsibility for the consequences arising out of the aforementioned information and strongly recommend you for a physical consultation in case of any queries or doubts.